Processing

Please wait...

Settings

Settings

Goto Application

1. WO2000028009 - BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR

Publication Number WO/2000/028009
Publication Date 18.05.2000
International Application No. PCT/AU1999/000993
International Filing Date 10.11.1999
Chapter 2 Demand Filed 05.06.2000
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
02Hepadnaviridae, e.g. hepatitis B virus
C12N 7/04 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2730/10122
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2730Reverse Transcribing DNA Viruses
00011Reverse Transcribing DNA Viruses
10011Hepadnaviridae
10111Orthohepadnavirus, e.g. hepatitis B virus
10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2730/10161
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2730Reverse Transcribing DNA Viruses
00011Reverse Transcribing DNA Viruses
10011Hepadnaviridae
10111Orthohepadnavirus, e.g. hepatitis B virus
10161Methods of inactivation or attenuation
C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Applicants
  • MELBOURNE HEALTH [AU]/[AU] (AllExceptUS)
  • LOCARNINI, Stephen, Alister [AU]/[AU] (UsOnly)
  • TORRESI, Joseph [AU]/[AU] (UsOnly)
  • EARNEST-SILVEIRA, Linda [SG]/[AU] (UsOnly)
  • BARTHOLOMEUSZ, Angeline, Ingrid [AU]/[AU] (UsOnly)
Inventors
  • LOCARNINI, Stephen, Alister
  • TORRESI, Joseph
  • EARNEST-SILVEIRA, Linda
  • BARTHOLOMEUSZ, Angeline, Ingrid
Agents
  • HUGHES, E., John, L.
Priority Data
PP 706011.11.1998AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR
(FR) COMPOSITIONS BIOLOGIQUES, LEURS CONSTITUANTS ET LEURS APPLICATIONS
Abstract
(EN)
The present invention relates generally to an isolated Hepatitis B virus (HBV) with a surface component exhibiting an altered immunological profile relative to a reference HBV. A reference HBV is considered herein to comprise a composite or consensus nucleotide or amino acid sequence from HBV genotypes A through F. The isolated HBV of the present invention is considered herein to be an HBV variant relative to the reference HBV. The altered immunological profile renders the HBV variants of the present invention less susceptible to vaccines directed to the surface component. The HBV variants of the present invention generally arise from selective pressure following one or both of anti-HBV chemical therapy and in particular chemical therapy aimed at disrupting HBV polymerase activity or function and/or following immune pressure directed to the surface component. Immune pressure may result from natural exposure to HBV or following vaccination with an avirulent or attenuated HBV or with a component of an HBV. The present invention further provides a recombinant polypeptide and derivatives and chemical equivalents thereof corresponding to the surface component of the HBV variants. The HBV variants and recombinant polypeptides and their derivatives and chemical equivalents of the present invention are useful in biological compositions capable of inducing a neutralizing immune response to the HBV variant.
(FR)
Cette invention a trait, d'une façon générale, à un virus isolé de l'hépatite B (VHB) possédant un constituant de surface faisant montre d'un profil immunologique modifié et ce, en comparaison d'un virus VHB de référence. Ce VHB de référence est réputé, dans le cadre de cette invention, renfermer une séquence nucléotidique ou aminoacide composite ou consensus provenant des génotypes A à F du VHB. Le VHB selon l'invention est réputé être un variant de VHB et ce, par rapport au VHB de référence. La modification du profil immunologique fait que les variants du VHB sont moins sensibles à des vaccins intéressant le constituant de surface. Ces variants sont le fait d'une pression sélective exercée sur le VHB et survenant après une chimiothérapie anti-VHB ou aux deux et, notamment, une chimiothérapie visant à interrompre l'activité ou la fonction VHB-polymérase, et/ou survenant après qu'une pression immune s'est exercée sur le constituant de surface. Cette pression immune peut résulter d'une exposition d'origine naturelle au VHB ou découler d'une vaccination par VHB avirulent ou atténué ou bien par vaccination par un constituant du VHB. Cette invention porte également sur un polypeptide de recombinaison ainsi que sur ses dérivés et équivalents chimiques correspondant au constituant de surface des variants du VHB. Ces variants, les polypeptides de recombinaison ainsi que leurs dérivés et équivalents chimiques se révèlent des plus utiles dans des compositions biologiques à même de déclencher une réponse immunitaire de neutralisation au variant du VHB.
Also published as
US09831686
Latest bibliographic data on file with the International Bureau